Dark

Check out our API

CATB
Catabasis Pharmaceuticals, Inc
stock NASDAQ

Inactive

Sep 8, 2021

8.54USD-6.972%(-0.64)98,872

Pre-market

0.00USD-100.000%(-9.18)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Sep 8, 2021

08:18AM EDT Catabasis Pharmaceuticals Changes Name To Astria Therapeutics, Inc RTTNews

08:05AM EDT Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus Benzinga

Sep 2, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021 Benzinga

07:07AM EDT Wedbush Initiates Coverage On Catabasis Pharmaceuticals with Outperform Rating, Announces Price Target of $16 Benzinga

Aug 25, 2021

06:11AM EDT HC Wainwright & Co. Upgrades Catabasis Pharmaceuticals to Buy, Announces $13 Price Target Benzinga

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

05:47AM EDT Catabasis Shares Trading Premarket on 1:6 Reverse Split Benzinga

Aug 9, 2021

04:13PM EDT Catabasis Pharmaceuticals Q2 EPS $(0.89) Down From $(0.53) YoY Benzinga

04:10PM EDT Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update Business Wire

Aug 4, 2021

08:00AM EDT Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference Business Wire

Jul 7, 2021

08:00AM EDT Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference Business Wire

Jun 17, 2021

01:44PM EDT Catabasis 13D Filing From Virdian Shows 9.99% Active Stake In Co. Benzinga

Jun 16, 2021

08:20AM EDT The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO Benzinga

Jun 15, 2021

04:37PM EDT Catabasis Pharma 13G Filing From Ra Capital Shows 7.5% Stake In Co. Benzinga

May 14, 2021

08:00AM EDT Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences Business Wire

May 13, 2021

04:51PM EDT Catabasis Pharmaceuticals Q1 EPS $(7.60) Down From $(0.50) YoY Benzinga

04:10PM EDT Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update Business Wire

May 12, 2021

10:15AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2021 Benzinga

07:35AM EDT Ladenburg Thalmann Initiates Coverage On Catabasis Pharmaceuticals with Buy Rating, Announces Price Target of $6 Benzinga

Mar 11, 2021

04:31PM EST Catabasis Pharmaceuticals Q4 EPS $(0.45) Up From $(0.55) YoY Benzinga

04:10PM EST Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update Business Wire

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 11, 2021 Benzinga

06:30AM EST Oppenheimer Upgrades Catabasis Pharmaceuticals to Outperform, Announces $5 Price Target Benzinga

Mar 2, 2021

08:00AM EST Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences Business Wire

Feb 8, 2021

05:24PM EST Catabasis Pharma 13D Filing From Perceptive Advisors Shows New 10.5% Stake In Co. Benzinga

Jan 29, 2021

03:15PM EST Mid-Afternoon Market Update: Dow Tumbles 450 Points; Catabasis Pharmaceuticals Shares Spike Higher Benzinga

12:18PM EST Mid-Day Market Update: Gold Gains Over 1%; eHealth Shares Plunge Benzinga

10:21AM EST Mid-Morning Market Update: Markets Open Lower; Caterpillar Earnings Top Expectations Benzinga

10:20AM EST Shares of Catabasis Pharmaceuticals Inc. (CATB) are currently surging over 60% after the biopharmaceutical company said it acquired Quellis Biosciences Inc., a privately-held emerging biopharmaceutical company focused on discovering best-in-class new molecules to treat serious rare diseases. RTTNews

08:19AM EST Catabasis Pharmaceuticals Announces Acquisition Of Quellis Biosciences Benzinga

08:05AM EST Catabasis Acquires Quellis Biosciences RTTNews

08:00AM EST Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc. Business Wire

Nov 12, 2020

04:13PM EST Catabasis Pharmaceuticals Q3 EPS $(0.56), Same YoY Benzinga

04:10PM EST Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update Business Wire

Nov 3, 2020

07:38AM EST The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga

Nov 2, 2020

03:21PM EST Catabasis Pharmaceuticals shares are trading lower after Wedbush downgraded the stock from Outperform to Neutral and announced a price target of $1.15 per share. Benzinga

07:20AM EST Wedbush Downgrades Catabasis Pharmaceuticals to Neutral, Announces $1.15 Price Target Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 30, 2020

08:55AM EDT Stocks Trading Near 52-Week Lows Before Open On Friday, Oct. 30, 2020: TUR, HPR, WBA, CATO, ASAN, SUMO, PSHG, IPOC, AKBA, CATB, INTC, DBVT Benzinga

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

Oct 29, 2020

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 28, 2020

08:59AM EDT Stocks Trading Near 52-Week Lows Before Open On Wednesday, Oct. 28, 2020: OXY, CTRM, PBF, BVXV, RIDE, FRO, CATB, NVCN, EURN, WFC, PSHG, MFGP, ZSAN, KERN, BP Benzinga

Oct 27, 2020

02:31PM EDT Mid-Afternoon Market Update: Crude Oil Rises 3%; Scholar Rock Shares Spike Higher Benzinga

12:19PM EDT Mid-Day Market Update: Harley-Davidson Jumps Following Strong Q3 Results; Catabasis Pharmaceuticals Shares Plummet Benzinga

10:55AM EDT Mid-Morning Market Update: Markets Mostly Lower; 3M Tops Q3 Estimates Benzinga

10:35AM EDT Benzinga's Top Upgrades, Downgrades For October 27, 2020 Benzinga

10:22AM EDT Mid-Morning Market Update: Markets Mostly Lower; 3M Tops Q3 Estimates Benzinga

09:02AM EDT Stocks Trading Near Their 52-Week Lows Before Open On Tuesday, Oct. 27, 2020: CATB, DBVT, ITRM, BVXV, BUR Benzinga

09:01AM EDT Stocks Trading Near 52-Week Lows Before Open On Tuesday, Oct. 27, 2020: CATB, DBVT, ITRM, BVXV, BUR Benzinga

08:25AM EDT The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga

06:47AM EDT Oppenheimer Downgrades Catabasis Pharmaceuticals to Perform Benzinga

06:39AM EDT HC Wainwright & Co. Downgrades Catabasis Pharmaceuticals to Neutral Benzinga

Oct 26, 2020

05:07PM EDT Catabasis Pharma Shares To Resume Trade At 5:30 p.m. EDT Benzinga

05:00PM EDT Catabasis Pharma Reports Results For Phase 3 PolarisDMD Trial Of Edasalonexent In Duchenne Muscular Dystrophy: Did Not Met Primary Endpoint Benzinga

05:00PM EDT Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy Business Wire

04:55PM EDT Catabasis Pharma Shares Halted News Pending Benzinga

Oct 1, 2020

09:30AM EDT Benzinga's Top Upgrades, Downgrades For October 1, 2020 Benzinga

06:19AM EDT HC Wainwright & Co. Initiates Coverage On Catabasis Pharmaceuticals with Buy Rating, Announces Price Target of $24 Benzinga

Sep 28, 2020

08:12AM EDT Catabasis Pharma Presents Information On Edasalonexent Program In Phase 3 Development For Duchenne Muscular Dystrophy RTTNews

08:07AM EDT Catabasis Pharmaceuticals Highlights Presentation Of Information On Edasalonexent, A Potential Foundational Therapy For Duchenne Muscular Dystrophy, At Virtual 25th International Congress Of The World Muscle Society Benzinga

08:00AM EDT Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle Society Business Wire

Sep 23, 2020

08:00AM EDT Catabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle Society Business Wire

Sep 21, 2020

08:12AM EDT Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer Benzinga

08:10AM EDT Catabasis Promotes Noah Clauser To CFO RTTNews

08:00AM EDT Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer Business Wire

Sep 8, 2020

08:00AM EDT Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences Business Wire

Sep 2, 2020

08:00AM EDT Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy Business Wire

Aug 10, 2020

04:39PM EDT Catabasis Pharmaceuticals Q2 EPS $(0.53) Misses $(0.45) Estimate Benzinga

04:10PM EDT Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress Business Wire

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 5, 2020

08:00AM EDT Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference Business Wire

Aug 4, 2020

08:06AM EDT Catabasis Pharmaceuticals And Bill & Melinda Gates Medical Research Institute To Study CAT-5571 In Drug-Sensitive And Drug-Resistant Tuberculosis Benzinga

Jul 27, 2020

08:00AM EDT Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th Business Wire

Jul 15, 2020

08:00AM EDT Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference Business Wire

Share